Sciensus partners with Sentynl Therapeutics to become the exclusive distribution partner of NULIBRY® in Europe

Sciensus, a life sciences business, to become the exclusive distribution partner for Sentynl’s drug NULIBRY in Europe.

UNITED STATES, July 12, 2024 /EINPresswire.com/ -- Sciensus, a life sciences business, specialising in patient access, engagement and insight solutions is pleased to announce that it has reached an agreement to become the exclusive distribution partner for Sentynl’s drug NULIBRY in Europe.

NULIBRY is the only medicine currently available for treatment for patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder known to impact fewer than 150 patients globally.

Sciensus will deliver both an early access programme and distribution services to support the market access and reimbursement processes of NULIBRY in Europe. NULIBRY currently holds an exceptional circumstances approval for marketing authorisation in Europe and requires a non-interventional post-authorisation safety study. Sciensus will be providing a digital and clinician-led service to support the development and capture of this critical and voluntary real-world data.

Sciensus has over 30 years of experience in supporting patients getting access to orphan drugs. Its global network is dedicated to accelerating this vital process – from early access all the way to full commercialisation, including patient support programs.

Darryn Gibson, CEO of Sciensus, said: “We are pleased to be partnering with Sentynl to provide programmes which will offer patients in Europe access to potentially-life saving medicines. Our exceptional experience and patient insights to support real world data allows us to deliver tailored solutions, better patient engagement and support, leading to more effective treatments, and elevated health outcomes for patients.”

“In partnership with Sciensus, we are proud to extend the reach of this innovative treatment to meet the needs of patients with MoCD Type A in Europe,” said Matt Heck, President & Chief Executive Officer of Sentynl. “This partnership marks another step forward in our mission to expand patient access to life-changing rare disease treatment.”

Notes to Editors:

For more information, please contact Sciensus@teneo.com

About Sciensus:
Sciensus is a life sciences business specialising in patient access, engagement and insight solutions. Every day we learn from patients and - together with our partners like pharmaceutical companies, the NHS and private providers - we use these learnings to develop the best approaches and support to help them get the most out of their therapy. Whether it’s about rare and orphan diseases, cancer or other life changing conditions - we provide bespoke end-to-end services built on exceptional insight and experience in our key markets to connect pharmaceutical companies, insurers and healthcare professionals to patients. So, whilst medicine is about science, these 70 million patient interactions across the UK and Europe have taught us that, at its best, it must firstly be about the science of people.

About Sentynl
Therapeutics Sentynl Therapeutics is a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. The company was acquired by the Zydus Group in 2017. Sentynl’s experienced management team has previously built multiple successful pharmaceutical companies. With a focus on commercialization, Sentynl looks to source effective and well-differentiated products across a broad spectrum of therapeutic areas to address unmet needs. Sentynl is committed to the highest ethical standards and compliance with all applicable laws, regulations and industry guidelines. For more information, visit https://sentynl.com.

About Molybdenum Cofactor Deficiency (MoCD) Type A
MoCD Type A is an autosomal recessive, inborn error of metabolism caused by mutations in the molybdenum cofactor synthesis 1 gene and characterized by a deficiency in molybdenum cofactor production, leading to a lack of molybdenum-dependent enzyme activity.1,2 The lack of activity leads to decreased sulfite oxidase activity with buildup of sulfite and secondary metabolites (such as S-sulfocysteine) in the brain, which causes irreversible neurological damage.2 MoCD Type A is an ultra-rare disease. The estimated prevalence of MoCD Type A in the European Union is 0.005 per 10,000. Based on these estimates, MoCD Type A is likely to be underdiagnosed. The most common presenting symptoms of MoCD Type A are seizures, feeding difficulties and encephalopathy. Patients with MoCD Type A who survive beyond infancy typically suffer from progressive brain damage, which presents in characteristic patterns on magnetic resonance imaging (MRI). This damage leads to severe psychomotor impairment and an inability to make coordinated movements or communicate with their environment.

References
1 Mechler K et al. Genet Med. 2015;17(12):965-970.
2 Schwarz G. Cur Op in Che Bio. 2016;31:179-187.

For U.S. Audiences Only

Kasia Banas
Teneo
kasia.banas@teneo.com